Previous close | 288.28 |
Open | 286.50 |
Bid | 286.79 x 800 |
Ask | 287.00 x 2200 |
Day's range | 285.10 - 289.63 |
52-week range | 187.16 - 311.88 |
Volume | |
Avg. volume | 1,196,970 |
Market cap | 41.312B |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | 14.62 |
EPS (TTM) | 19.62 |
Earnings date | 15 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 322.26 |
How far off is Biogen Inc. ( NASDAQ:BIIB ) from its intrinsic value? Using the most recent financial data, we'll take a...
Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.
CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie